AdrianM.Di BisceglieMD

PubMed

• 6 citations
  Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.
  Norah A Terrault, Anna S Lok, Abdus S Wahed, Marc G Ghany, Robert P Perrillo
  The American Journal of Gastroenterology. 2023-07-01
• 3 citations
  Within-host quantitation of anellovirus genome complexity from clinical samples.
  Peng Peng, Yanjuan Xu, Rajeev Aurora, Adrian M Di Bisceglie, Xiaofeng Fan
  Journal of Virological Methods. 2022-04-01
• 1 citations
  Michael Charles Kew - Frontrunner in Hepatology.
  Chris Kassianides, Geoffrey Dusheiko, Adrian Di Bisceglie, Jay H Hoofnagle
  Journal of Hepatology. 2021-12-06

Journal Articles

• TG4040 Immunotherapeutic with Peginterferon/Ribavirin in Chronic HCV Infection: a Randomized Phase II Study  
  Di Bisceglie, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, Tanasescu C, Flisiak R, Romero-Gomez M, Fich A, Bataille V, Toh M-L, Hennequi M, Zerr P..., Gastroenterology, 1/1/2014
• VX-222, a Non-Nucleoside NSSB Polymerase Inhibitor, in Telaprevir-Based Regimens for Genotype 1 Hepatitis C Virus Infection  
  Di Bisceglie AM, Sulkowski M, Gane E, Jacobson IM, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang EZ, Kauffman R, Asmal M, Koziel MJ, European J Gastroenterol Hepatol, 1/1/2014
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection  
  Afdhal N, Reddy R, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM et al, N Engl J Med, 1/1/2014
• Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis  
  Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM et al, N Engl J Med, 1/1/2014
• Retreatment of HCV with ABT-450/r-Ombitasvir and dasabuvir with ribavirin  
  Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS, Wedermeyer, Tam E, Desmond P, Jensen DM, Di Bisceglie AM et al, N Engl J Med, 1/1/2014
• Prevention of hepatocellular carcinoma due to hepatitis B: are we there yet?  
  Di Bisceglie AM, Clin Gastro Hepatol, 1/1/2014
• Telbivudine Improves Renal Function in Patients with Chronic Hepatitis B  
  Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papaptheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A, Gastroenterology, 1/1/2013
• Potentially Curative Treatment in Patients with Hepatocellular Cancer-Results from the Liver Cancer Research Network  
  Kanwal, Fasiha; Befeler, Alex; Marrero, Jorge; Chari, Ravi; Afdhal, Nid; Morgan, Timothy; Robert, Lewis; Mohanty, Smruti; Schwartz, Jonathan M; Van Thiel, David; Di Bi..., Ali Pharm Ther, 1/1/2012
• Hepatitis C virus induces epithelial-mesenchymal transition in primary human hepatocytes  
  Bose SK, Meyer K, Di Bisceglie AM, Ray RB, Ray R, J Virol, 1/1/2012
• Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A  
  Bhanja Chowdhury J. Shrivastava S. Steele R. Di Bisceglie AM. Ray R. Ray RB, J Virol, 1/1/2012
• EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma  
  Di Bisceglie AM (as a clinical practice Guideline Member), J Hepatol, 1/1/2012
• The history of the department of Internal Medicine at Saint Louis University  
  Di Bisceglie AM, Manning C, Holyoke A, Missouri Medicine, 1/1/2012
• Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma  
  Gish RG. Lencioni R. Di Bisceglie AM. Raoul JL. Mazzaferro V, Expert review of gastroenterology & hepatology, 1/1/2012
• Transcriptional repression of C4 complement by hepatitis C virus proteins  
  Banerjee A, Mazumdar B, Meyer K, Di Bisceglie AM, Ray RB, Ray R, Journal of Virology, 5/1/2011
• Maintenance Peginterferon Therapy and Other Factors Associated with Hepatocellular Carcinoma in Patients with Advanced Hepatitis C  
  Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR, HALT..., Gastroenterol, 1/1/2011
• Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon  
  Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; for the HALT-..., Hepatology, 1/1/2011
• Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection  
  Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM et al for the ADVANCE Study Team, N Engl J Med, 1/1/2011
• A prospective study of the rate of progression in compensated histologically advanced chronic hepatitis C  
  Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C..., Hepatology, 1/1/2011
• Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C  
  Lok AS, Everhart JE, Di Bisceglie AM, Kim, H-Y, Hussain M, Morgan TR and the HALT-C trial group, Hepatology, 1/1/2011
• Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation  
  Wang W, Lin J, Xu Y, Brunt EM, Fan X, Di Bisceglie AM, Biochem Biophys Res Comm, 1/1/2011
• Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma  
  Comunale MA, Wang M, Rodemich-Betesh L, Hafner J, Lamontagne A, Klein A, Marrero J, Di Bisceglie AM, Gish R, Block T, Mehta A, Cancer Epidemiology, Biomarkers & Prevention, 1/1/2011
• Prospects for personalizing antiviral therapy for HCV with pharmacogenetics  
  Tavis JE, Donlin MJ, Aurora R, Fan X, and Di Bisceglie AM, Genome Medicine, 1/1/2011
• Procarbazine Hepatotoxicity: Case Report and Review of the Literature  
  Fesler MJ, Becker-Koepke S, Di Bisceglie AM, Petruska PJ, Pharmacotherapy, 1/1/2010
• Des-gamma-carboxy Prothrombin and alpha-fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma  
  Lok AS, Sterling R, Everhart J, Wright E, Hoefs J, Di Bisceglie AM, Morgan T, Kim H-Y, Lee W, Bonkovsky H, Dienstag J, Gastroenterology, 1/1/2010
• A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus  
  Singal AG, Volk ML, Jensen J, Di Bisceglie AM, Schoenfeld PS, Clin Gastro Hepatol, 1/1/2010
• Join now to see all

Books/Book Chapters

• Schiff's Diseases of The Liver 
  Chapter: Benign tumors, nodules and cystic diseases of the liver. 
  Page 937 - 976Di Bisceglie AM, Befeler ASEditors: Schiff ER, Maddrey WC, Sorrell MF.Wiley-BlackwellEdition 11th,2012
• Cancer: Principles and Practice of Oncology 
  Chapter: Cancer of the Liver. 
  Page 997 - 1018Bartlett DL, Di Bisceglie AM, Dawson LAEditors: DeVita, Lawrence and Rosenberg.Lippincott Williams and Wilkins, PhiladelphiaEdition 9th,2011
• Liver Cirrhosis and Its Development. Falk Symposium 
  Chapter: Hepatitis C-evolving therapeutic strategies. 
  Page 156 - 160Di Bisceglie AMEditors: Boyer JL, Blum HE, Maier K-P, Sauerbruch T, Stalder GA.2011
• Sleisinger and Fordtran's Gastrointestinal and Liver Disease 
  Chapter: Tumors and cysts of the liver. 
  Page 1569 - 1592Di Bisceglie AM, Befeler ASEditors: Feldman M, Friedman LS, Brandt LJ.Saunders Elsevier, PhiladelphiaEdition 9th,2010
• DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology 
  Chapter: Cancer of the liver. 
  Page 1129 - 1156Bartlett DL, Di Bisceglie AM, Dawson LAWolters Kluwer/Lippincott Williams and Wilkins, Philadelphia2008
• Internal Medicine. Just the Facts 
  Chapter: Diseases of the pancreas. 
  Page 343 - 347Di Bisceglie AMEditors: Schmitz PG, Martin KJ.McGraw Hill, New York2008
• Internal Medicine. Just the Facts 
  Chapter: Liver and biliary diseases. 
  Page 338 - 342Di Bisceglie AMEditors: Schmitz PG, Martin KJ.McGraw Hill, New York2008
• Infectious Disease. A Scientific American Reader 
  Chapter: The unmet challenge of hepatitis C. 
  Page 47 - 57Di Bisceglie AM and Bacon BRUniversity of Chicago Press, Chicago2008
• Schiff's Diseases of the Liver 
  Chapter: Nodular and cystic lesions. 
  Page 1231 - 1251Di Bisceglie AM, Befeler ASLippincott Williams & Wilkins, PhiladelphiaEdition 10th,2007
• Comprehensive Clinical Hepatology 
  Chapter: Hepatitis C. 
  Page 235 - 248Di Bisceglie AMMosby Elsevier, PhiladelphiaEdition 2nd,2006
• Comprehensive Clinical Hepatology 
  Chapter: Imaging of the liver. 
  Page 123 - 136Bieneman BK, Di Bisceglie AMMosby Elsevier, PhiladelphiaEdition 2nd,2006
• Handbook of Management Issues in Hepatitis C 
  Chapter: Screening for hepatocellular carcinoma. 
  Page 119 - 130Bialecki E and Di Bisceglie AM2005
• Management Issues in Hepatitis C Infection 
  Chapter: Screening for hepatocellular carcinoma. 
  Page 118 - 121Bialecki E, Di Bisceglie AMEditors: McHutchison J.Science Press, London2004
• Handbook of Liver Disease 
  Chapter: Hepatic tumors. 
  Page 339 - 348Di Bisceglie AMEditors: Friedman LS, Keeffe EB.Churchill Livingstone, PhiladelphiaEdition 2nd,2004
• Digestive Disease Self-Evaluation Program (DDSEP III) for the American Gastroenterological Association 
  Chapter: Viral Hepatitis. 
  Page 271 - 288Di Bisceglie AM2004
• Viral Hepatitis 
  Chapter: Hepatitis and hepatocellular carcinoma. 
  Page 133 - 138Di Bisceglie AMEditors: Buti M, Esteban R.Accion Medica SA, Madrid2003
• Hepatitis C-Current Diagnosis and Emerging Treatment Options 
  Page 1 - 16Di Bisceglie AMThomson PDR, Montvale, NJ2003
• Atlas of the Liver 
  Chapter: Tumors of the liver. 
  Page 287 - 301Di Bisceglie AMEditors: Maddrey WC and Feldman M.Current Medicine, Philadelphia2003
• Digestive Disease Self-Evaluation Program (DDSEP II) for the American Gastroenterological Association 
  Chapter: Viral Hepatitis. 
  Di Bisceglie AM2002
• Viruses and Liver Cancer 
  Chapter: Treatment of hepatocellular carcinoma. 
  Page 161 - 172Befeler A and Di Bisceglie AMEditors: Tabor E.Elsevier Science B.V., The Netherlands2002
• Textbook of Viral Hepatitis 
  Chapter: Treatment in patients with normal ALT and/or minimal histologic lesions. 
  Page 158 - 167Lyra AC and Di Bisceglie AMEditora Atheneu, Sao PauloEdition 1st,2002
• Therapies for Viral Hepatitis 
  Chapter: Compartmentalization of hepatitis C viral quasispecies. 
  Page 123 - 130Fan X, Castro-Lyra A, Di Bisceglie AMEditors: Schinazi RF, Rice C, and Sommadossi J-P.Elsevier Science, The Netherlands2002
• Clinics in Liver Disease 
  Chapter: Liver Tumors. 
  Di Bisceglie, AMW.B. Saunders Co., Philadelphia2001
• Hepatitis C 
  Chapter: Hepatitis and hepatocellular carcinoma. 
  Page 265 - 275Di Bisceglie AMAcademic Press2000
• Liver Disease: Diagnosis and Management 
  Chapter: Management of chronic viral hepatitis. 
  Page 98 - 106Di Bisceglie AM, Hoofnagle JHEditors: Di Bisceglie AM, Bacon BR.Churchill Livingstone, New York1999
• Join now to see all

Abstracts/Posters

• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 394 Treatment-Experienced Adults With...
  S Zeuzem, I Jacobson, T Baykal, RT Marinho, F Poordad, M Bourliere, M Sulkowski, H Wedemeyer, E Tam, P Desmond, D Jensen, AM Di Bisceglie, P Varunok, T Hassanein, J Xi..., EASL, 1/1/2014
• All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-infected Patients: The Phase...
  Paul Kwo, Rajender K. Reddy, Paul Pockros, Adrian M. Di Bisceglie, Sanjeev Arora, Jenny C. Yang, Hadas Dvory-Sobol, Yanni Zhu, Phil S. Pang, William T. Symonds, John G..., Digestive Diseases Week, 1/1/2014
• Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients: Results From Phase 2 and Phase 3 Trials.
  . Fried MW, Di Bisceglie AM, et al, Hepatology, 1/1/2014
• SVR12 Rate of 95.7% in 209 HCV Genotype 1-Infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin.
  Jacobson IM< DuFour J-F, Enejosa J, de Knegt RJ, Ferenci P, Reynaert H, Di Bisceglie AM et al, Hepatology, 1/1/2014
• ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Effic...
  Nelson DR, Reddy KR, Di Bisceglie AM et al, Hepatology, 1/1/2014
• Safety and Efficacy of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) + Ribavirin (RBV) in Patients with Genotype 1: Interim Results of a Prospective, Observati...
  Sulkowski MS, Vargas HE, Di Bisceglie AM et al, Hepatology, 1/1/2014
• Virologic Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir (BOC) or Telaprevir (TVR)...
  Di Bisceglie AM, Kuo A, Rustgi VK et al, AASLD, 11/1/2013
• Estimated impact of screening and antiviral treatment on prevention of HBV reactivation associated with cancer chemotherapy.
  Desai RJ, Schnitzler MA, Di Bisceglie AM, AASLD, 11/1/2013
• Combination of the NS5A Inhibitor, GS-5885, the NS3 Protease Inhibitor, GS-9451, and Pegylated Interferon Plus Ribavirin in Treatment Experienced Patients with Genotyp...
  Everson GT, Di Bisceglie A, Vierling JM et al, J Hepatol, 1/1/2013
• Phase II HCVac Study of TG4040 immunotherapeutic in combination with PegIFNalpha2a and ribavirin in genotype 1 CHC treatment naive patients: SVR24 Final Results.
  Wedemeyer H, Janczewska Kazek E, Mazur W, Stanciu C, Habersetzer F, Carreno V, Di Bisceglie AM et al, J Hepatol, 1/1/2013
• HCV-TARGET: A Longitudinal, Observational Study Of North American Patients With Chronic Hepatitis C (HCV) Treated With Boceprevir Or Telaprevir.
  Fried MW, Reddy KR, Di Bisceglie AM et al, J Hepatol, 1/1/2013
• HCV Treatment Selection and Duration Decision-Making: Real-World Issues with HCV RNA and HCV Genotype Assays Used in Clinical Practice.
  MW Fried, M Vainorius, KR Reddy, AM Di Bisceglie, DM Jensen, IM Jacobson, M Sulkowski, N Terrault, K Bergquist, TG Stewart, JA Peter, and DR Nelson for the HCV-TARGET ..., Global Antiviral Journal; HEP DART, 1/1/2013
• Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE phase 3 studies.
  Poordad F, Sulkowski M, Reddy R, Di Bisceglie AM, Zeuzem S, Afdhal N, Bengtsson L, Wright CI, Kauffman RS, Adda N, Can J Gastro; Digestive Diseases Week 2011, 1/1/2012
• Sustained virologic response rates and viral resistance profiles were similar in patients treated with a telaprevir-based regimen regardless of liver fibrosis stage.
  Marcellin P, Sullivan J, Fried MW, Kieffer TL, Dusheiko GM, Martin EC, Nelson DR, Di Bisceglie AM et al, Can J Gastro; Hepatology, 1/1/2012
• Vx-222/telaprevir in combination with peginterferon-alfa-2A and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: Zenith study, SVR12 interim ...
  Nelson DR, Gane EJ, Jaconson IM, Di Bisceglie AM et al, Can J Gastro; Hepatology, 1/1/2012
• Telaprevir in combination with peginterferon alfa-2A and ribavirin: Analyses of pre-defined subpopulations in the pahse 3 ADVANCE trial.
  Marcellin P, Jaconson I, Zeuzem S, Bzowej N, Muir AJ, Dusheiko G, Reddy R, Adda N, Bengtsson L, Kauffman RS, George S, Di Bisceglie AM, J Hepatology, 1/1/2011
• Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the ADVANCE and Illuminate phase 3 studies.
  Sulkowski MS, Reddy R, Afdhal NH, Di Bisceglie AM et al, J Hepatology, 1/1/2011
• Vx-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C: Zenith study interim results.
  Di Bisceglie AM et al, J Hepatology, 1/1/2011
• Telaprevir in combination with peginterferon alfa-2a and ribavirin: analyses of pre-defined subpopulations in the phase 3 ADVANCE trial.
  Di Bisceglie AM, Dusheiko GM, Muir AJ, Zeuzem S, Marcellin P, Bzowej NH, Jacobson IM, Adda N, Bengtsson L, Kauffman RS, George S, Reddy R, Digestive Diseases Week, 1/1/2011
• Patient Mortality and Liver Transplantation during the HALT-C Trial: Relationship to Chronic Liver Disease and Interferon Therapy.
  Di Bisceglie AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow K, Stoddard A, Digestive Diseases Week, New Orleans, 1/1/2010
• Progression of Advanced Chronic Hepatitis C (CHC): Further Follow-up Results from the HALT-C Trial.
  Dienstag JL, Bonkovsky HL, Kim H-Y, Seeff LB, Di Bisceglie AM, Szabo G, Wright EC, Digestive Diseases Week, New Orleans, 1/1/2010
• Association of host pharmacodynamic effects and virologic response to peginterferon alfa-2A/ribavirin in patients with chronic hepatitis C.
  Chung RT, Di Bisceglie AM, Poordad FF et al, J Hepatol, 1/1/2010
• Improved sustained virologic response (SVR) rates in "difficult-to-cure" patients treated with telaprevir in combination with peginterferon alfa-2A and ribavirin: An a...
  Manns MP, Muir AJ, Adda N, McHutchison JG, Terrault N, Bengtsson L, George S, Di Bisceglie AM, J Hepatol, 1/1/2010
• Early virological response profiles with telaprevir (T) in combination with peginterferon-alfa-2A (P) and ribavirin in genotype 1 HCV treatment-naive and treatment-exp...
  Poordad F, McHutchison JG, Shiffman ML, Berg T, Muir AJ, Manns MP, Di Bisceglie AM et al, J Hepatol, 1/1/2010
• Pharmacogenomic analysis reveals improved virologic response in all IL-28B genotypes in naive genotype 1 chronic HCV patients treated with GI-5005 therapeutic vaccine ...
  McHutchison JG, Thompson AJ, Jacobson IM, Boyer TD, Schiff ER, Everson GT, Vierling JM, Shiffman ML, Brown RS, Di Bisceglie AM et al, J Hepatol, 1/1/2010
• Join now to see all

Other

• Audio CD: "Management of chronic hepatitis C in the era of direct-acting antiviral agents." 
  Di Bisceglie AM, Audio Digest Gastroenterology, Vol 26 (Issue 17)
  9/7/2012
• The Clinician's Companion VII: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C. 
  Di Bisceglie AM, "Relationship between chronic HCV infection and hepatocellular carcinoma.", Projects in Knowledge, p
  1/1/2005
• "Digestive Diseases Week 2004 CME Program" 
  Di Bisceglie AM
  http://www.medscape.com/viewprogram/3103
  1/1/2004
• Natural history of hepatitis C. 
  Di Bisceglie AM, Clinical Care Options for Hepatitis, Annual Update, IMedOptions, pp. 3-12
  1/1/2003
• Nonalcoholic liver disease: An emerging view of its significance and management. 
  Di Bisceglie AM, Medscape Gastroenterology/Digestive Diseases Week Conference Coverage
  http://www.medscape.com/viewprogram/1846
  1/1/2002
• "Raising hepatitis C awareness." 
  Di Bisceglie AM, HealthTalk Interactive's Hepatitis C Education Network
  http://www.healthtalk.com
  1/30/2001
• Liver diseases. (Instructional pamphlet) 
  Di Bisceglie AM, SLUCare/Tenet
  1/1/2001
• Hepatocellular carcinoma. In, The Clinician's Companion V: Expert perspectives on contemporary issues in hepatitis C. Part 2: Insights into the pathogenesis, treatment... 
  Di Bisceglie AM, Rakela J, Projects in Knowledge, pp. 11-15
  1/1/2001
• The Clinician's Companion IV: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C. Part 3: Insights into pathogenesis, treatment effects, and management... 
  Di Bisceglie AM, Kwo PY, Rustgi VK, Projects in Knowledge, pp. 9-12
  1/1/2001
• "How do you manage the patient with hepatitis B and hepatitis C dual infection?" 
  Di Bisceglie AM, Medscape "Ask the Experts-Hepatitis C"
  12/14/2000
• New developments in hepatocellular carcinoma. 
  Di Bisceglie AM, American Association for the Study of Liver Diseases 51st Annual Meeting and Postgraduate Course
  http://www.medscape.com/Medscape/CNO/2000/AASLD/Story
  1/1/2000
• "Viral Hepatitis." 
  Di Bisceglie AM, Digestive Diseases Self-Education Program II (DDSEP) for the American Gastroenterological Associatio
  1/1/2000
• Rising Incidence of Hepatocellular Carcinoma. 
  Di Bisceglie AM, Medscape AASLD-Advances in Hepatocellular Carcinoma
  http://gastroenterology.medscape.com/Medscape/CNO/1999/AASLD/public/index-AASLD.html
  12/1/1999
• The Clinician's Companion III: Expert perspectives on contemporary clinical issues in hepatitis C. (CD-ROM) 
  Di Bisceglie AM, Education Initiatives in Gastroenterology Meeting
  6/18/1999
• Emerging therapies for chronic hepatitis C. 
  Di Bisceglie AM, Audiotape: Beyond Monotherapy: Next Generation Therapies for Chronic Hepatitis C; Education Initiati
  New Orleans - 5/17/1998
• Hepatocellular carcinoma. 
  Di Bisceglie AM, The clinician's companion: expert perspectives on contemporary clinical issues in hepatitis C, pages
  1/1/1997
• (Tape) Hepatitis C recommendations. 
  Di Bisceglie AM, Audio Journal of Haematology
  1/1/1994
• Combined infection with hepatitis B and hepatitis C. 
  Di Bisceglie AM, Hepatitis forum, Abbott Labs, page 12
  1/1/1994
• Extra-hepatic manifestations of chronic viral hepatitis. 
  Shakil OA, Di Bisceglie AM, 'L' Internista'
  1/1/1994
• (Tape) Treatment of chronic viral hepatitis. 
  Di Bisceglie AM, Practical Reviews in Gastroenterology
  1/1/1989
• A randomized controlled trial of a 4 month course of recombinant human alpha interferon in patients with chronic type B hepatitis. 
  Di Bisceglie AM, Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi VK, Avigan MI, Park Y, Waggoner JG, Jones EA. In, Schellekens H, Cantell K, Proceedings of the 1986 ISIR/TNO Meeting; Martinus Nijhoff
  Dordrecht, The Netherlands - 1/1/1987
• Join now to see all